Calidi Biotherapeutics Falls 5% After NYSE Non-Compliance Notice on Stockholders' Equity

Calidi Biotherapeutics Inc. (CLDI) said it received a notice of non-compliance from NYSE American LLC over a deficiency in the biotechnology company's stockholders' equity. The notice was issued on Sept. 25, 2026, according to a Friday announcement. Shares fell 5% following the disclosure. The listing warning signals the company fails to meet NYSE American's continued listing standards on minimum stockholders' equity. Calidi did not disclose the specific shortfall or its remediation plan. Non-compliance notices do not trigger immediate delisting; companies typically receive a cure period to submit a plan to regain compliance. Calidi trades on NYSE American under the ticker CLDI.